News | August 02, 2021
Glenmark signs agreement with SaNOtize to manufacture NONS
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
The company posted net profit of Rs.89.20 crores for the period ended June 30, 2020.
Winlevi has been approved by the United States FDA as a novel drug with a unique mechanism of action for the topical treatment of acne in patients 12 years and older
The Cephalosporin Injectables plant has a total capacity of 26.4 million vials per year while Ethiopia is having a demand for 16 million vials
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
The company is confident of commencing production at both Mahad and Chiplun units soon
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
State-of-the-art R&D lab expands technical feasibility capabilities for long-acting delivery of small molecules, biologics, nucleotides
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
Subscribe To Our Newsletter & Stay Updated
